Pemetrexed-Induced Nephrogenic Diabetes Insipidus

Fung, Enrica; Anand, Shuchi; Bhalla, Vivek

doi:10.1053/j.ajkd.2016.04.016

Cited by 8 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there is now accumulating evidence for the nephrotoxic potential of pemetrexed itself. Several case reports describe incidents of (sub)acute kidney injury during or after pemetrexed therapy [22][23][24][25][26][27][28][29]. In the PARAMOUNT study, during pemetrexed maintenance, 7.8 % of patients developed renal impairment (versus 2.3 % in the placebo group) and 4 % of patients discontinued therapy due to nephrotoxicity [30].…”

Section: Introductionmentioning

confidence: 99%

Cumulative pemetrexed dose increases the risk of nephrotoxicity

et al. 2020

View full text Add to dashboard Cite

Introduction: Pemetrexed is a pharmacotherapeutic cornerstone in the treatment of non-small cell lung cancer. As it is primarily eliminated by renal excretion, adequate renal function is essential to prevent toxic exposure. There is growing evidence for the nephrotoxic potential of pemetrexed, which even becomes a greater issue now combined immuno-chemotherapy prolongs survival. Therefore, the aim of this study was to describe the incidence of nephrotoxicity and related treatment consequences during pemetrexed-based treatment. Methods: A retrospective cohort study was conducted in the Jeroen Bosch Hospital, Den Bosch, the Netherlands. All patients that received at least 1 cycle of pemetrexed based therapy were included in the dataset. The primary outcome was defined as a ≥25 % reduction in eGFR. Additionally, the treatment consequences of decreased renal function were assessed. Logistic regression was used to identify risk factors for nephrotoxicity during treatment with pemetrexed. Results: Of the 359 patients included in this analysis, 21 % patients had a clinically relevant decline in renal function after treatment and 8.1 % of patients discontinued treatment due to nephrotoxicity. Cumulative dose (≥10 cycles of pemetrexed based therapy) was identified as a risk factor for the primary outcome measure . Conclusion:This study shows that patients on pemetrexed-based treatment are at risk of developing renal impairment. Risk significantly increases with prolonged treatment. Renal impairment is expected to become an even greater issue now that pemetrexed-based immuno-chemotherapy results in longer survival and thus longer treatment duration.

show abstract